TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Sees Large Growth in Short Interest

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 128,400 shares, an increase of 3,278.9% from the January 31st total of 3,800 shares. Based on an average trading volume of 210,100 shares, the short-interest ratio is currently 0.6 days.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price target on shares of TC Biopharm from $112.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 6th.

TC Biopharm Price Performance

Shares of TCBP stock opened at $2.17 on Friday. The stock has a 50-day moving average of $6.67 and a 200-day moving average of $37.58. TC Biopharm has a 1-year low of $1.91 and a 1-year high of $523.20.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.